Correlation of HER2/neu over expression, p53 protein accumulation and steroid receptor status with tumor characteristics: An Iranian study of breast cancer patients

Iranian Journal of Public Health

Volumn 37, Issue 3, 2008, Pages 19-28

  Morandi Marjaneh, M ^a   Homaei Shandiz, F ^b   Shamsian, S A A ^a   Eftekhar Zadek Mashhadi, I ^a   Hedayati Moghadam, M R ^a  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast Cancer; HER2 neu; Iran; p53; Stage; Steroid Receptor

Indexed keywords

EID: 56549130536     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Wood WC, Muss HB, Solin LJ, Olopade OI (2005). Malignant tumors of the breast. In: Cancer: Principles and Practice of Oncology. Ed, DeVita V, Hellman S, Rosenberg S. Lippincott Williams & Wilkins, 7th ed. Philadelphia, pp. 1423-25.
2. Subramaniam DS, Isaacs C (2005). Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol, 6(2): 147-59.
3. Glissmeyer M (2007). Reviewing prognostic factors in breast cancer management. JAAPA, 20(5): 42-6.
4. Martin M (2006). Molecular biology of breast cancer. Clin Transl Oncol, 8(1): 7-14.
5. Nicolini A, Carpi A, Tarro G (2006). Biomolecular markers of breast cancer. Front Biosci, 1(11): 1818-43.
6. Payne SJ, Bowen RL, Jones JL, Wells CA (2008). Predictive markers in breast cancer- the present. Histopathology, 52(1): 82-90.
7. Walker RA (2007). Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol, Nov 23 [Epub ahead of print]
8. Yarden Y (2001). Biology of HER2/neu and its importance in breast cancer [review] Oncology, 61(suppl 2): 1-13.
9. Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M (2007). Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. In Vivo, 21(4): 673-78.
10. Otsuka K, Ishioka C (2007). TP53 mutations and molecular epidemiology. Gan To Kagaku Ryoho, 34(5): 683-89.
11. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, et al. (2004). Coexistence of HER2/neu over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res, 6(1): R24-30.
12. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P (2005). Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J, 11(4): 278-80.
13. Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, et al. (2007). Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol, 25(28): 4423-30.
14. Francis G, Beadle G, Thomas S, Mengersen K, Stein S (2006). Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Pathology, 38(5): 391-8.
15. Al-Ahwal MS (2006). HER-2 positivity and correlations with other histopathologic features in breast cancer patients-hospital based study. J Pak Med Assoc, 56(2): 65-8.
16. Stark A, Kapke A, Schultz D, Brown R, Linden M, Raju U (2008). Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women. Breast Cancer Res Treat, 107(3): 405-14.
17. Report on national cancer registery in Iran by ministry of health and medical education, 2003.
18. Quaem Hospital [online]. Available from: URL: http://www.mums.ac.ir/ quaem/fa/index Accessed Feb 11 2007.
19. Omid Hospital [online]. Available from: URL: http://www.mums.ac.ir/omid/ fa/index Accessed Feb 11 2007.
20. Elston CW, Ellis IO (1998). Assessment of histological grade. In: The breast. Vol. 13. Ed, Elston CW, Ellis IO. Churchill Livingstone, Edinburgh, New York, pp. 356-84.
21. Wood WC, Muss HB, Solin LJ, Olopade OI (2005). Malignant tumors of the breast. In: Cancer: Principles and Practice of Oncology. Ed, DeVita V, Hellman S, Rosenberg S. Lippincott Williams & Wilkins, 7th ed. Philadelphia, pp. 1422-23.
22. HercepTest™ Interpretation Manual [online]. Available from: URL: http://www.dako.com Accessed Feb 11 2007.
23. Harvey JM, Clark GM, Osborne CK, Allred DC (1999). Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 17: 1474-81.
24. Mofid B, Jalali Nadooshan MR, Kiani L, Zayeri F (2004). Evaluation of relation between HER2 proto-oncogen with prognostic factors of breast cancer. Research in Medicine, 28(1): 29-32.
25. Hashemi E, Montazeri A, Akbari ME, Najafi M, Haghighat Sh, et al. (2006). Role of tumor markers in breast cancer recurrence. Journal of Medical School of Gilan University of Medical Sciences, 15(57): 28-32.
26. Najafi B, Fakheri T, Fadakare Sogheh Gh (2006). Relationship of HER2 with other clinical-pathological diagnostic criteria in breast cancer patients. Journal of Medical School of Gilan University of Medical Sciences, 15(57): 21-7.
27. Dunnwald LK, Rossing MA, Li CI (2007). Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Research, 9(1): Available online http://breast-cancer-research.com/content/9/1/R6.
28. Summary Proceedings: 29th Annual Symposium of the American Society of Breast Disease April 14-16, 2005, Las Vegas, Nevada.
29. Bowen RL, Stebbing J, Jones LJ (2006). A review of the ethnic differences in breast cancer. Pharmacogenomics, 7(6): 935-42.
30. Amend K, Hicks D, Ambrosone CB (2006). Breast cancer in African-American women: differences in tumor biology from European- American women. Cancer Res, 66(17): 8327-30.
31. Fong M, Henson DE, Devesa SS, Anderson WF (2006). Inter- and intra-ethnic differences for female breast carcinoma incidence in the continental United States and in the state of Hawaii. Breast Cancer Res Treat, 97(1): 57-65. Epub 2005 Dec 14.
32. Huang CS, Chen YC, Wang M, Lin JK, Chang KJ (1995). HER-2/neu overexpression in Chinese breast cancers: correlation with other prognostic factors. J Formos Med Assoc, 94(11): 660-65.
33. Rashed MM, Ragab NM, Galal MK. The association of Her-2/neu over expression in relation with p53 nuclear accumulation, hormonal receptor status and common clinicopathological prognostic parameters in a series of Egyptian women with invasive ductal carcinoma. Internet J Pathol [online]. Available from: URL: http://www.ispub.com/ostia/ index.php?xmlFilePath=journals/ijpa/vol4n1/her2.xml Accessed Feb 11 2007.
34. Lampe B, Genz T, Maassen V, Mikorey S, Klosterhalfen T (1992). Correlation of c-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors. Arch Gynecol Obstet, 251(1): 45-50.
35. Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, et al. (2003). A comparison of five immunohistochemical biomarkers and HER2/neu gene amplification by fluorescence in Situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer, 98(8): 1587-95.
36. Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N, Martin PM, et al (2006). Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features. International Journal of Cancer, 62(2): 138-44.